• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

HC009 mRNA 疫苗对 SARS-CoV-2 的免疫原性和保护效力。

Immunogenicity and protective efficacy of the HC009 mRNA vaccine against SARS-CoV-2.

机构信息

Nucleic Acid Medicine Innovation Center, Zhejiang Haichang Biotech Co., Ltd., Hangzhou, Zhejiang, China.

出版信息

Front Immunol. 2024 Jul 26;15:1416375. doi: 10.3389/fimmu.2024.1416375. eCollection 2024.

DOI:10.3389/fimmu.2024.1416375
PMID:39131158
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11310568/
Abstract

With the rapid global spread of COVID-19 and the continuous emergence of variants, there is an urgent need to develop safe and effective vaccines. Here, we developed a novel mRNA vaccine, HC009, based on new formulation by the QTsome delivery platform. Immunogenicity results showed that the prime-boost immunization strategy with HC009 was able to induce robust and durable humoral immunity, as well as Th1-biased cellular responses in rodents or non-human primates (NHPs). After further challenge with live SARS-CoV-2 virus, HC009 provided adequate protection against virus infection in hACE2 transgenic mice. Therefore, HC009 could provide significant immune protection against SARS-CoV-2.

摘要

随着 COVID-19 在全球范围内的迅速传播和不断出现的变异株，我们迫切需要开发安全有效的疫苗。在这里，我们基于 QTsome 递送平台的新配方，开发了一种新型的 mRNA 疫苗 HC009。免疫原性结果表明，HC009 的初免-加强免疫策略能够在啮齿动物或非人类灵长类动物（NHPs）中诱导出强大且持久的体液免疫和 Th1 偏向的细胞反应。在进一步用活 SARS-CoV-2 病毒进行攻毒后，HC009 为 hACE2 转基因小鼠提供了针对病毒感染的充分保护。因此，HC009 可以为 SARS-CoV-2 提供显著的免疫保护。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4962/11310568/cc12315b5da6/fimmu-15-1416375-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4962/11310568/1e8b523fc629/fimmu-15-1416375-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4962/11310568/d2d59ff50919/fimmu-15-1416375-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4962/11310568/c5c42b41eafa/fimmu-15-1416375-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4962/11310568/00545fc8fdf0/fimmu-15-1416375-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4962/11310568/cc12315b5da6/fimmu-15-1416375-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4962/11310568/1e8b523fc629/fimmu-15-1416375-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4962/11310568/d2d59ff50919/fimmu-15-1416375-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4962/11310568/c5c42b41eafa/fimmu-15-1416375-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4962/11310568/00545fc8fdf0/fimmu-15-1416375-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4962/11310568/cc12315b5da6/fimmu-15-1416375-g005.jpg

相似文献

1
Immunogenicity and protective efficacy of the HC009 mRNA vaccine against SARS-CoV-2.HC009 mRNA 疫苗对 SARS-CoV-2 的免疫原性和保护效力。
Front Immunol. 2024 Jul 26;15:1416375. doi: 10.3389/fimmu.2024.1416375. eCollection 2024.
2
The safety, immunogenicity, and efficacy of heterologous boosting with a SARS-CoV-2 mRNA vaccine (SYS6006) in Chinese participants aged 18 years or more: a randomized, open-label, active-controlled phase 3 trial.安全性、免疫原性和异源加强用 SARS-CoV-2 mRNA 疫苗（SYS6006）在中国 18 岁及以上人群中的效果：一项随机、开放标签、阳性对照的 3 期临床试验。
Emerg Microbes Infect. 2024 Dec;13(1):2320913. doi: 10.1080/22221751.2024.2320913. Epub 2024 Feb 29.
3
A decavalent composite mRNA vaccine against both influenza and COVID-19.一种针对流感和 COVID-19 的十价复合 mRNA 疫苗。
mBio. 2024 Sep 11;15(9):e0066824. doi: 10.1128/mbio.00668-24. Epub 2024 Aug 6.
4
Three in one: An effective and universal vaccine expressing heterologous tandem RBD trimer by rabies virus vector protects mice against SARS-CoV-2.三合一：狂犬病病毒载体表达异源串联 RBD 三聚体的有效且通用疫苗可保护小鼠免受 SARS-CoV-2 感染。
Antiviral Res. 2024 Jul;227:105905. doi: 10.1016/j.antiviral.2024.105905. Epub 2024 May 11.
5
Heterologous mRNA/MVA delivering trimeric-RBD as effective vaccination regimen against SARS-CoV-2: COVARNA Consortium.异源mRNA/MVA递送三聚体RBD作为针对SARS-CoV-2的有效疫苗接种方案：COVARNA联盟
Emerg Microbes Infect. 2024 Dec;13(1):2387906. doi: 10.1080/22221751.2024.2387906. Epub 2024 Aug 8.
6
Cellular and humoral immunogenicity of a SARS-CoV-2 mRNA vaccine in patients on haemodialysis.血液透析患者中 SARS-CoV-2 mRNA 疫苗的细胞和体液免疫原性。
EBioMedicine. 2021 Aug;70:103524. doi: 10.1016/j.ebiom.2021.103524. Epub 2021 Aug 12.
7
Co-administration of recombinant BCG and SARS-CoV-2 proteins leads to robust antiviral immunity.联合使用重组卡介苗和 SARS-CoV-2 蛋白可诱导强烈的抗病毒免疫。
Vaccine. 2024 Oct 3;42(23):126203. doi: 10.1016/j.vaccine.2024.126203. Epub 2024 Aug 22.
8
Immunogenicity of Low-Dose Prime-Boost Vaccination of mRNA Vaccine CV07050101 in Non-Human Primates.mRNA疫苗CV07050101低剂量初免-加强免疫接种在非人灵长类动物中的免疫原性
Viruses. 2021 Aug 19;13(8):1645. doi: 10.3390/v13081645.
9
A single-dose mRNA vaccine provides a long-term protection for hACE2 transgenic mice from SARS-CoV-2.单剂 mRNA 疫苗为 hACE2 转基因小鼠提供了针对 SARS-CoV-2 的长期保护。
Nat Commun. 2021 Feb 3;12(1):776. doi: 10.1038/s41467-021-21037-2.
10
Preclinical evaluation of a SARS-CoV-2 mRNA vaccine PTX-COVID19-B.SARS-CoV-2 mRNA 疫苗 PTX-COVID19-B 的临床前评估。
Sci Adv. 2022 Jan 21;8(3):eabj9815. doi: 10.1126/sciadv.abj9815. Epub 2022 Jan 19.

引用本文的文献

1
TXNIP promotes viral replication by disrupting MAVS-mediated antiviral signaling and serves as a therapeutic target for antiviral therapy.硫氧还蛋白相互作用蛋白（TXNIP）通过破坏线粒体抗病毒信号蛋白（MAVS）介导的抗病毒信号传导来促进病毒复制，并作为抗病毒治疗的一个治疗靶点。
Redox Biol. 2025 Jul 5;85:103756. doi: 10.1016/j.redox.2025.103756.
2
A bivalent mRNA vaccine against RSV infection in rodent models.一种用于啮齿动物模型中预防呼吸道合胞病毒（RSV）感染的二价mRNA疫苗。
Front Immunol. 2025 Mar 24;16:1542592. doi: 10.3389/fimmu.2025.1542592. eCollection 2025.

本文引用的文献

1
Phase I study of a non-S2P SARS-CoV-2 mRNA vaccine LVRNA009 in Chinese adults.一项在中国成年人中进行的非 S2P SARS-CoV-2 mRNA 疫苗 LVRNA009 的 I 期研究。
Vaccine. 2023 Nov 22;41(48):7297-7306. doi: 10.1016/j.vaccine.2023.10.065. Epub 2023 Nov 3.
2
Immunogenicity and protective effects of recombinant bivalent COVID-19 vaccine in mice and rhesus macaques.重组双价 COVID-19 疫苗在小鼠和恒河猴中的免疫原性和保护效果。
Vaccine. 2023 Aug 14;41(36):5283-5295. doi: 10.1016/j.vaccine.2023.06.086. Epub 2023 Jun 30.
3
DOTAP: Structure, hydration, and the counterion effect.
DOTAP：结构、水合作用和抗衡离子效应。
Biophys J. 2023 Mar 21;122(6):1086-1093. doi: 10.1016/j.bpj.2023.01.031. Epub 2023 Jan 26.
4
A novel mRNA vaccine, SYS6006, against SARS-CoV-2.一种新型的针对 SARS-CoV-2 的 mRNA 疫苗，SYS6006。
Front Immunol. 2023 Jan 5;13:1051576. doi: 10.3389/fimmu.2022.1051576. eCollection 2022.
5
Antitumor Activity of Anti-miR-21 Delivered through Lipid Nanoparticles.脂质纳米颗粒递送的抗 miR-21 抗肿瘤活性。
Adv Healthc Mater. 2023 Jan;12(6):e2202412. doi: 10.1002/adhm.202202412. Epub 2022 Dec 9.
6
Safety and superior immunogenicity of heterologous boosting with an RBD-based SARS-CoV-2 mRNA vaccine in Chinese adults.基于RBD的新型冠状病毒mRNA疫苗异源加强免疫在中国成年人中的安全性和卓越免疫原性
Cell Res. 2022 Aug;32(8):777-780. doi: 10.1038/s41422-022-00681-3. Epub 2022 Jun 14.
7
Lipid nanoparticle-encapsulated mRNA antibody provides long-term protection against SARS-CoV-2 in mice and hamsters.脂质纳米颗粒包裹的 mRNA 抗体为小鼠和仓鼠提供了针对 SARS-CoV-2 的长期保护。
Cell Res. 2022 Apr;32(4):375-382. doi: 10.1038/s41422-022-00630-0. Epub 2022 Feb 24.
8
Intranasal Delivery of MVA Vector Vaccine Induces Effective Pulmonary Immunity Against SARS-CoV-2 in Rodents.鼻腔内递送 MVA 载体疫苗可在啮齿动物中诱导针对 SARS-CoV-2 的有效肺部免疫。
Front Immunol. 2021 Nov 11;12:772240. doi: 10.3389/fimmu.2021.772240. eCollection 2021.
9
Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in mice.变异的 SARS-CoV-2 mRNA 疫苗在小鼠中作为初级或加强系列疫苗具有广泛的中和作用。
Vaccine. 2021 Dec 17;39(51):7394-7400. doi: 10.1016/j.vaccine.2021.11.001. Epub 2021 Nov 8.
10
Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis.在健康成年人中，SARS-CoV-2 变异 mRNA 疫苗加强针的安全性和免疫原性：一项中期分析。
Nat Med. 2021 Nov;27(11):2025-2031. doi: 10.1038/s41591-021-01527-y. Epub 2021 Sep 15.